Basis: Trailing twelve months (TTM). Source: stored company filings and market data; unavailable inputs remain N/A.
Is the earnings per share (EPS) high or low?
The earnings per share (EPS) of -2.47 is 67% above its 5-year average of -7.51, near the high end of its 5-year range (-16.68–-2.31).
32.33% above its 12-month average of -3.65.
Reported quarterly EPS; no daily interpolation. Q2 FY2026 (2026-06-30): -0.66.
EPS growth vs the same fiscal quarter in the prior fiscal year, last 33 comparable quarters.
EARNINGS PER SHARE (EPS)
-2.47
EARNINGS PER SHARE (EPS) AVG TTM
-3.65
EARNINGS PER SHARE (EPS) AVG 3Y
-5.00
EARNINGS PER SHARE (EPS) AVG 5Y
-7.51
EARNINGS PER SHARE (EPS) AVG 10Y
-125.96
EARNINGS PER SHARE (EPS) AVG 15Y
-282.21
EARNINGS PER SHARE (EPS) AVG 20Y
-1957.26
CURRENT VS TTM AVG
+32.33%
CURRENT VS 3Y AVG
+50.62%
CURRENT VS 5Y AVG
+67.13%
CURRENT VS 10Y AVG
+98.04%
CURRENT VS 15Y AVG
+99.12%
CURRENT VS 20Y AVG
+99.87%
Oruka Therapeutics, Inc.
Market Cap
$4.84B
Earnings Per Share (EPS)
-2.47
TTM Avg
-3.65
3Y Avg
-5.00
5Y Avg
-7.51
Market Cap
$4.85B
Earnings Per Share (EPS)
-0.13
TTM Avg
-3.38
3Y Avg
-5.70
5Y Avg
-8.99
Market Cap
$4.90B
Earnings Per Share (EPS)
-14.56
TTM Avg
-1.16
3Y Avg
-2.58
5Y Avg
-2.86
Market Cap
$4.73B
Earnings Per Share (EPS)
-3.43
TTM Avg
-1.80
3Y Avg
-1.89
5Y Avg
-2.15
Market Cap
$4.70B
Earnings Per Share (EPS)
0.13
TTM Avg
-0.06
3Y Avg
-0.31
5Y Avg
-0.46
Market Cap
$5.08B
Earnings Per Share (EPS)
2.42
TTM Avg
2.12
3Y Avg
1.80
5Y Avg
1.31
Market Cap
$4.61B
Earnings Per Share (EPS)
0.62
TTM Avg
-0.43
3Y Avg
-0.91
5Y Avg
-0.91
Market Cap
$4.65B
Earnings Per Share (EPS)
1.33
TTM Avg
1.25
3Y Avg
1.21
5Y Avg
0.93
Market Cap
$5.08B
Earnings Per Share (EPS)
-0.95
TTM Avg
-0.56
3Y Avg
-0.99
5Y Avg
-0.97
| NAME | MARKET CAP | EARNINGS PER SHARE (EPS) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Oruka Therapeutics, Inc. (ORKA) | $4.84B | -2.47 | -3.65 | -5.00 | -7.51 |
| Dianthus Therapeutics, Inc. (DNTH)vs › | $4.85B | -0.13 | -3.38 | -5.70 | -8.99 |
| Mirum Pharmaceuticals, Inc. (MIRM)vs › | $4.90B | -14.56 | -1.16 | -2.58 | -2.86 |
| Definium Therapeutics, Inc. (DFTX)vs › | $4.73B | -3.43 | -1.80 | -1.89 | -2.15 |
| LifeStance Health Group, Inc. (LFST)vs › | $4.70B | 0.13 | -0.06 | -0.31 | -0.46 |
| Merit Medical Systems, Inc. (MMSI)vs › | $5.08B | 2.42 | 2.12 | 1.80 | 1.31 |
| BillionToOne, Inc. (BLLN)vs › | $4.61B | 0.62 | -0.43 | -0.91 | -0.91 |
| Option Care Health, Inc. (OPCH)vs › | $4.65B | 1.33 | 1.25 | 1.21 | 0.93 |
| Erasca, Inc. (ERAS)vs › | $5.08B | -0.95 | -0.56 | -0.99 | -0.97 |
| Scholar Rock Holding Corporation (SRRK)vs › | $5.18B | -3.31 | -2.88 | -2.49 | -2.72 |
Trailing EPS (TTM)
$-2.47
Forward EPS (Est.)
$-2.40
P/E Ratio
N/A
Formula: EPS = Net Income / Weighted Average Shares Outstanding
Why EPS matters:
EPS (Earnings Per Share) represents the portion of a company's profit allocated to each outstanding share. Higher EPS indicates greater profitability on a per-share basis.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | EARNINGS PER SHARE (EPS) |
|---|---|
| 2025-12-31 | -2.31 |
| 2024-12-31 | -4.99 |
| 2023-12-31 | -4.44 |
| 2022-12-31 | -8.27 |
| 2021-12-31 | -16.68 |
| 2020-12-31 | -8.40 |
| 2019-12-31 | -49.79 |
| 2018-12-31 | -123.73 |
| 2017-12-31 | -382.87 |
| 2016-12-31 | -390.96 |
| 2015-12-31 | -393.12 |
| 2014-12-31 | -710.64 |
| 2013-12-31 | -1572.48 |
| 2012-12-31 | -2933.25 |
| 2011-12-31 | -4808.16 |
| 2010-12-31 | -8981.28 |
| 2009-12-31 | -12882.00 |
| 2008-12-31 | -4666636.00 |
| 2007-12-31 | -41731.00 |
| 2006-12-31 | -468115.00 |
| 2005-12-31 | -313891.00 |
